Human Vaccines & Immunotherapeutics最新文献_第9页

Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China. 江苏省带状疱疹疫苗覆盖率及上市后不良事件监测

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/21645515.2025.2449714

Xiang Sun, Lei Zhang, Tingting Zhang, Jinning Sun, Yan Xu, Li Liu, Yuan Bao Liu, Ran Hu, YaLi Fu, Zhiguo Wang, Hui Sun

{"title":"Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China.","authors":"Xiang Sun, Lei Zhang, Tingting Zhang, Jinning Sun, Yan Xu, Li Liu, Yuan Bao Liu, Ran Hu, YaLi Fu, Zhiguo Wang, Hui Sun","doi":"10.1080/21645515.2025.2449714","DOIUrl":"https://doi.org/10.1080/21645515.2025.2449714","url":null,"abstract":"To analyze the coverage rate of adult herpes zoster (HZ) vaccine and the incidence of Adverse event following immunization (AEFI) in Jiangsu province, China. The vaccination information of HZ vaccine in people aged 50 years and above in Jiangsu province in 2023 and the AEFI information of HZ vaccine from 2020 to 2023 were collected through the Jiangsu Province vaccination management information system and China AEFI information management system, and the vaccination rate and AEFI incidence of HZ vaccine were analyzed. The overall vaccination rate among individuals aged 50 years and above was merely 0.19%. About 20% of vaccinated individuals (12,821 people) received only the first dose, failing to complete the recommended two-dose regimen. A total of 43 and 217 cases of AEFIs following vaccination were reported after administration of the HZ vaccine during the periods of 2020-2021 and 2022-2023, respectively, resulting in reporting rates (RRs) of 240.7 and 201.2 per 100,000 doses, correspondingly. The majority of AEFIs following vaccination with HZ vaccines were common reactions, while rare reactions and coincidental events accounted for only 1.5% and 0.4% of cases, respectively. Over 55% of AEFIs occurred within 30 minutes post-vaccination , with fever, allergic eruptions, and drowsiness being the most reported systemic symptoms, and redness and induration being the main symptoms at the injection site. Despite the proven safety profile of the HZ vaccine, its coverage remains significantly low among individuals aged 50 years and above in Jiangsu Province, China as of 2023. The majority of AEFIs were mild and commonly observed. To enhance the comprehensiveness of post-marketing safety data, it is imperative to conduct further active surveillance studies.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2449714"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/21645515.2025.2450120

Jelena Tica, Veronica V Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih, Javier Ruiz-Guiñazú

{"title":"Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.","authors":"Jelena Tica, Veronica V Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih, Javier Ruiz-Guiñazú","doi":"10.1080/21645515.2025.2450120","DOIUrl":"10.1080/21645515.2025.2450120","url":null,"abstract":"We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 1010 viral particles [vp]) in healthy adolescents aged 12-17 years. Participants were randomly assigned to receive Ad26.COV2.S at reduced dose levels of 0.625 × 1010 (0.5 mL), 1.25 × 1010 (0.5 mL) or 2.5 × 1010 (0.5 mL or low volume 0.25 mL) vp in a 1- or 2-dose (56-day interval) primary schedule. Adolescents who received a 1-dose primary schedule received a 2.5 × 1010 vp booster dose 6 months later. Safety and humoral immunogenicity were assessed up to 6 months post-last vaccination. All regimens were well tolerated, with no safety concerns identified. Local and systemic solicited AEs in adolescents were consistent with the known safety profile in adults. All 1- and 2-dose Ad26.COV2.S primary schedules elicited robust peak Spike-binding antibody responses and virus neutralizing titers against the reference strain, in participants with and without preexisting SARS-CoV-2 immunity. Immune responses were durable for at least 6 months. Spike-binding antibody responses were comparable to those elicited in young adults aged 18-25 years who received a standard dose of Ad26.COV2.S in Phase 3 efficacy studies Reduced doses/dose volume of Ad26.COV2.S had an acceptable safety profile and elicited robust humoral immune responses in adolescents aged 12-17 years. All 1- and 2-dose schedules elicited Spike-binding antibody responses that were comparable to an adult population in whom efficacy has been demonstrated using a higher vaccine dose. (clinicaltrials.gov NCT05007080).","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2450120"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pneumococcal vaccines in China.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-30 DOI: 10.1080/21645515.2025.2460274

Shanshan Wang, Bin Li, Qiong Chen, Chune Wang, Bin Wang, Qiang Ye, Yinghua Xu

引用次数: 0

Developing a practical tool for measuring parental vaccine hesitancy: A people-centered validation approach in Dutch.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-17 DOI: 10.1080/21645515.2025.2466303

Daphne Bussink-Voorend, Jeannine L A Hautvast, Tim Wiersma, Reinier Akkermans, Marlies E J L Hulscher

{"title":"Developing a practical tool for measuring parental vaccine hesitancy: A people-centered validation approach in Dutch.","authors":"Daphne Bussink-Voorend, Jeannine L A Hautvast, Tim Wiersma, Reinier Akkermans, Marlies E J L Hulscher","doi":"10.1080/21645515.2025.2466303","DOIUrl":"10.1080/21645515.2025.2466303","url":null,"abstract":"Vaccine hesitancy (VH) about routine childhood vaccinations drives falling vaccine uptake rates. This is a major public health challenge and therefore important to monitor uniformly. The challenge is that different methods are used to measure VH and that, in non-English language, there may not be an unequivocal translation of VH terminology. We aimed to develop and validate a method to assess VH in a simple and self-reported manner, with a mixed-methods study using a people-centered approach with a diverse group of parents and illustrated in Dutch. In the quantitative part, parents were asked to rate experienced vaccine hesitancy on a 10-point Likert scale, using five differently worded Dutch translations for VH. We analyzed internal consistency with Cronbach's alpha and correlation with the short parental attitudes about childhood vaccination (PACV-5) scale. A total of 532 parents participated in the survey. We found that the five worded alternatives measured the same construct, indicated by a Cronbach's alpha of 0.95. The wording resembling 'doubt' showed highest correlation with the PACV-5 score (coefficient -0.525, p < .001). In the qualitative part of this study, we conducted cognitive interviews with 12 lower educated parents to evaluate the comprehensibility and interpretation of the question and VH translations. The findings reinforced and added to the quantitative findings that 'doubt' is the preferred wording. Based on the integrated results, we developed the Vaccine Hesitancy Assessment (VHA) tool. We encourage its use for monitoring purposes at the time of decision-making as this may provide a window of opportunity for decision-support interventions.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2466303"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis on willingness and its influencing factors of influenza vaccination among HCWs in Quzhou in 2022-2023 influenza season.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-14 DOI: 10.1080/21645515.2025.2466296

Wangfeng Zheng, Mei Lu, Canya Fu, Fei Zhao, Wenjie Xu, Xiaoying Gong, Quanjun Fang, Zhiying Yin, Canjie Zheng

{"title":"Analysis on willingness and its influencing factors of influenza vaccination among HCWs in Quzhou in 2022-2023 influenza season.","authors":"Wangfeng Zheng, Mei Lu, Canya Fu, Fei Zhao, Wenjie Xu, Xiaoying Gong, Quanjun Fang, Zhiying Yin, Canjie Zheng","doi":"10.1080/21645515.2025.2466296","DOIUrl":"10.1080/21645515.2025.2466296","url":null,"abstract":"The aim of this study was to ascertain the current status of healthcare workers' (HCWs) willingness to receive the influenza vaccination and to identify the influencing factors in Quzhou. A self-administered questionnaire was used to investigate the cognition and vaccination intention of in-service HCWs in 10 medical and health institutions in Quzhou from July to September in 2022, and the influencing factors of vaccination intention were analyzed by Logistic regression. A total of 228 questionnaires were returned, with the effective rate of 95.2%. The influenza vaccination coverage rate of HCWs in 2021-2022 season was 22.6%, and the willingness rate in 2022-2023 season was 56.7%. Logistic regression showed that township medical institutions, junior professional titles, people who thought vaccines were effective and people who had been vaccinated with influenza vaccine in the past increased their willingness to get influenza vaccine. The influenza vaccination coverage rate of HCWs in Quzhou is low, and the vaccination willingness is affected by many factors. Providing free vaccines for HCWs and targeted education are the key measures to reduce the vaccine hesitancy for HCWs.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2466296"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PfCSP-ferritin nanoparticle malaria vaccine antigen formulated with aluminum-salt and CpG 1018® adjuvants: Preformulation characterization, antigen-adjuvant interactions, and mouse immunogenicity studies. 用铝盐和 CpG 1018® 佐剂配制的 PfCSP-铁蛋白纳米颗粒疟疾疫苗抗原：制剂前表征、抗原-佐剂相互作用和小鼠免疫原性研究。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-04 DOI: 10.1080/21645515.2025.2460749

John M Hickey, Nitya Sharma, Max Fairlamb, Jennifer Doering, Yetunde Adewunmi, Katherine Prieto, Giulia Costa, Benjamin Wizel, Elena A Levashina, Nicholas J Mantis, Jean-Philippe Julien, Sangeeta B Joshi, David B Volkin

{"title":"PfCSP-ferritin nanoparticle malaria vaccine antigen formulated with aluminum-salt and CpG 1018® adjuvants: Preformulation characterization, antigen-adjuvant interactions, and mouse immunogenicity studies.","authors":"John M Hickey, Nitya Sharma, Max Fairlamb, Jennifer Doering, Yetunde Adewunmi, Katherine Prieto, Giulia Costa, Benjamin Wizel, Elena A Levashina, Nicholas J Mantis, Jean-Philippe Julien, Sangeeta B Joshi, David B Volkin","doi":"10.1080/21645515.2025.2460749","DOIUrl":"10.1080/21645515.2025.2460749","url":null,"abstract":"Circumsporozite protein (CSP), the most abundant surface protein in parasitic Plasmodium falciparum (Pf) sporozoite and an attractive target for malaria vaccine design, has been shown to induce protective humoral response in humans. In this work, we characterized and formulated a promising recombinant PfCSP immunogen (155) candidate consisting of two PfCSP epitopes (i.e. junction, NANP repeat) fused to H. pylori apoferritin forming a 24-mer nanoparticle. In addition, two N-linked glycans were engineered to mitigate possible anti-apoferritin immune responses, and a universal T-cell epitope was included to further enhance immunogenicity. Physicochemical characterization of the 155 antigen was performed including primary structure, post-translational modifications, conformational stability, and particle size. A competitive ELISA was developed to assess antigen binding to a PfCSP-specific mAb. The in vitro antigenicity of the 155 antigen was measured upon formulation with adjuvants, including aluminum-salts (i.e. AlhydrogelTM, Adju-PhosTM) and the TLR-9 agonist CpG 1018®, when freshly combined and after storage at different temperatures over 3 months. The in vivo immunological impact of various adjuvanted formulations of the 155 antigen was investigated in mice. The results support the formulation of 155 with AlhydrogelTM + CpG 1018® adjuvants as a promising recombinant malaria vaccine candidate from both a pharmaceutical and immunological perspective.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2460749"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving HPV-related health literacy in the Austrian population - A participatory research approach.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-25 DOI: 10.1080/21645515.2025.2469334

Magdalena Meikl, Tanja Karl, Anja Schuster, Gertie Janneke Oostingh

{"title":"Improving HPV-related health literacy in the Austrian population - A participatory research approach.","authors":"Magdalena Meikl, Tanja Karl, Anja Schuster, Gertie Janneke Oostingh","doi":"10.1080/21645515.2025.2469334","DOIUrl":"10.1080/21645515.2025.2469334","url":null,"abstract":"Human papilloma virus (HPV) infections are widespread and affect a main part of the population. Long-term risks of such infections include the development of HPV-induced cancers. Although available, preventive measures are not utilized by the Austrian population to their fullest extent. Only 40% of all Austrians have completed the vaccination programme and only 46% are aware of HPV. This may be attributed to a lack of awareness or an ineffective approach in disseminating information to raise awareness about this health issue. Our aim was to determine which knowledge on HPV infections and vaccinations is present in the Austrian population and to identify the preferred mode of communication for receiving information on health-related issues, including HPV. This objective was implemented in the context of a participatory research project together with citizen scientists, whereby a target group-oriented survey was developed. Data from 889 survey participants, analyzed with descriptive statistics, demonstrated significant gender- and age-related differences in HPV knowledge and information-seeking behavior. Men and individuals under 18 were significantly less informed, especially regarding transmission routes and HPV-related diseases. Women were more aware of the vaccine's benefits and have higher vaccination rates. The use of clear, concise content and personal stories can foster engagement and address misperceptions. Customized HPV awareness campaigns and an integration of HPV education into school curricula should be implemented to facilitate early knowledge acquisition and vaccination uptake.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2469334"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global distribution and characteristics of pneumococcal serotypes in adults.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-27 DOI: 10.1080/21645515.2025.2469424

Haruka Maeda, Konosuke Morimoto

引用次数: 0

Attitudes and acceptance of vaccination against neglected tropical diseases: A multi-country study in Asia.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-06 DOI: 10.1080/21645515.2025.2471702

Li Ping Wong, Hai Yen Lee, Haridah Alias, Farhana Nishat Seheli, Abhishek Lachyan, Di Khanh Nguyen, Jamil Ahmed, Zhijian Hu, Yulan Lin

{"title":"Attitudes and acceptance of vaccination against neglected tropical diseases: A multi-country study in Asia.","authors":"Li Ping Wong, Hai Yen Lee, Haridah Alias, Farhana Nishat Seheli, Abhishek Lachyan, Di Khanh Nguyen, Jamil Ahmed, Zhijian Hu, Yulan Lin","doi":"10.1080/21645515.2025.2471702","DOIUrl":"10.1080/21645515.2025.2471702","url":null,"abstract":"This study aims to explore the willingness of individuals to be vaccinated against NTDs in Asian countries and China. Between June and December 2023, an anonymous cross-sectional survey was carried out in five Asian countries alongside China. Overall, 48.4% indicated being somewhat willing and 29.2% expressing extreme willingness to receive NTDs vaccination. High attitude scores (adjusted odds ratio [aOR] = 1.54, 95% confidence interval (CI): 11.35-1.75) was associated with higher willingness to be vaccinated against NTDs. The odds of accepting the NTDs vaccine increased among individuals without occupational exposure to NTDs (aOR = 1.46, 95% CI: 1.27-1.68). Those residing in very clean environments exhibited heightened odds of willingness (aOR = 2.94, 95% CI: 2.10-4.11), whereas individuals in somewhat dirty environments demonstrated reduced odds of willingness (aOR = 0.74, 95% CI: 0.56-0.98) compared to the baseline group (very dirty local environment). Moreover, a higher score in sanitation facilities also correlated with increased odds of willingness to receive the NTDs vaccine (aOR = 1.41, 95% CI: 1.21-1.64). The study highlighted key strategies for improving NTDs vaccine uptake in Asian countries, including China, such as fostering positive attitudes toward the vaccine and enhancing perception of infection risks.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2471702"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Demographics and clinical burden of disease among RSV-hospitalized older adults in Italy: A retrospective cohort study.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-24 DOI: 10.1080/21645515.2025.2479334

Anna Puggina, Melania Dovizio, Alexander Domnich, Alen Marijam, Chiara Veronesi, Caterina Rizzo, Marta Vicentini, Luca Degli Esposti, Giovanna Elisa Calabrò, Maria João Fonseca

{"title":"Demographics and clinical burden of disease among RSV-hospitalized older adults in Italy: A retrospective cohort study.","authors":"Anna Puggina, Melania Dovizio, Alexander Domnich, Alen Marijam, Chiara Veronesi, Caterina Rizzo, Marta Vicentini, Luca Degli Esposti, Giovanna Elisa Calabrò, Maria João Fonseca","doi":"10.1080/21645515.2025.2479334","DOIUrl":"10.1080/21645515.2025.2479334","url":null,"abstract":"Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection and can lead to severe disease in older adults or those with comorbidities. This analysis aims to evaluate the demographic and clinical burden of RSV hospitalizations among older adults in Italy and inform potential preventative strategies. Adults aged ≥50 years with ≥1 hospitalization discharge diagnosis for RSV from 2010 to 2021 were included. Demographic characteristics before the first RSV hospitalization and clinical outcomes during this hospitalization and the 12 months following are described. Of the 243 patients, mean (SD) age was 73.7 (13.1) years, 40.7% were male, and the most common comorbidities were chronic obstructive pulmonary disease (37.9%), diabetes (21.8%), and heart failure (15.2%). Mean length of index hospitalization was 17.0 days, during which 9.1% of patients died. At index or during the 12-month follow-up, 5.8% had an intensive care unit admission, 61.3% were prescribed antibiotics, 8.2% had a stroke, and 3.3% had an acute myocardial infarction. During the 12-month follow-up, approximately, half of patients experienced worsening of preexisting comorbidities, with notable rates of re-hospitalization and mortality (44.4% and 29.6%). This study shows a high clinical burden of RSV among older adults in Italy, emphasizing a need for improved RSV surveillance, and may guide policymakers and healthcare providers in making informed recommendations for, and implementation of, RSV vaccination in Italy.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2479334"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0